Related Experiment Video

Updated: Jun 23, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Melanoma: molecular pathogenesis and emerging target therapies (Review)

Alessia E Russo1, Elena Torrisi, Ylenia Bevelacqua

  • 1Department of Biomedical Sciences, University of Catania, I-95124 Catania, Italy.

International Journal of Oncology
|May 9, 2009
PubMed

Insights

Malignant melanoma, a resistant skin cancer, involves activated Ras/Raf/MEK/ERK (MAPK) and PI3K/AKT (AKT) pathways. Understanding these signaling pathways is crucial for developing new melanoma treatments.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Malignant melanoma is an aggressive skin cancer with a poor prognosis in advanced stages.
  • Current therapeutic strategies show limited efficacy against melanoma.
  • Constitutive activation of Ras/Raf/MEK/ERK (MAPK) and PI3K/AKT (AKT) signaling pathways is common in melanoma.

Purpose of the Study:

  • To review key studies on signaling pathways implicated in melanoma development.
  • To explore novel therapeutic strategies for melanoma based on pathway dysregulation.

Main Methods:

  • Literature review of relevant studies on melanoma signaling pathways.
  • Analysis of the roles of MAPK and AKT pathways in melanomagenesis.
  • Identification of therapeutic targets within these pathways.

Main Results:

  • BRAF mutations contribute to melanoma development and MAPK pathway activation.
  • MAPK pathway activation promotes cell cycle progression and inhibits apoptosis.
  • PTEN deletion leads to AKT activation, which can paradoxically decrease downstream MAPK signaling.

Conclusions:

  • Dysregulation of MAPK and AKT pathways is central to melanoma pathogenesis.
  • Targeting these signaling pathways offers promising avenues for novel melanoma therapies.
  • Further research into these pathways may lead to improved treatment outcomes for melanoma patients.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models05:33

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.